<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="43553">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02539316</url>
  </required_header>
  <id_info>
    <org_study_id>15-PP-03</org_study_id>
    <nct_id>NCT02539316</nct_id>
  </id_info>
  <brief_title>Pilot Study: Hepatoprotective Role of SMOFlipid® Used in Short-term Parenteral Nutrition in an Onco-Hematology Pediatric Population</brief_title>
  <acronym>SMOFPILOT</acronym>
  <official_title>Pilot Study: Hepatoprotective Role of SMOFlipid® Used in Short-term Parenteral Nutrition in an Onco-Hematology Pediatric Population</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nice</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nice</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Parenteral nutrition (PN) is part of supportive care in oncology Pediatric when the
      patient's nutritional status justifies it and enteral is impossible. In the literature,
      hepatotoxicity, cholestasis type, standard emulsions of soy oil-based (type Médialipide®) is
      described in the context of a long-term PN especially in premature infants. It results in an
      increase in gammaGT. The most recent use of lipid emulsions containing Omega 3 (Smoflipid),
      was studied in the adult population and in the preterm in the PN on short and long, with the
      finding of a hepatoprotection. Investigators do not find a single retrospective study about
      it in Pediatric Onco-Hematology. No prospective studies have been performed in the
      population of Onco-Hematology. The objective of this study is to evaluate the impact of the
      use of SMOFlipid® in parenteral nutrition on early occurrence of cholestasis compared with
      Médialipides in a short-term use of parenteral nutrition in an Onco-Hematology pediatric
      population.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Anticipated">June 2016</completion_date>
  <primary_completion_date type="Anticipated">June 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>dosage of γGT in UI/l</measure>
    <time_frame>Baseline</time_frame>
    <description>to evaluate the impact of the use of SMOFlipid® in parenteral nutrition on early occurrence of cholestasis compared with Médialipides in a short-term use of parenteral nutrition in an Onco-Hematology pediatric population.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>dosage of γGT in UI/l</measure>
    <time_frame>at day 5</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>dosage of γGT in UI/l</measure>
    <time_frame>7 days after the end of parenteral nutrition</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>asat, alat, PAL, LDH, total bilirubin CRP</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>asat, alat, PAL, LDH, total bilirubin CRP</measure>
    <time_frame>at day 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>asat, alat, PAL, LDH, total bilirubin CRP</measure>
    <time_frame>7 days after the end of parenteral nutrition</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Triglycerids Digestive tolerance (vomiting)</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Triglycerids Digestive tolerance (vomiting)</measure>
    <time_frame>at day 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Triglycerids Digestive tolerance (vomiting)</measure>
    <time_frame>7 days after the end of parenteral nutrition</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infectious episodes (numbers, duration)</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infectious episodes (numbers, duration)</measure>
    <time_frame>at day 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infectious episodes (numbers, duration)</measure>
    <time_frame>7 days after the end of parenteral nutrition</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nutritionnal status</measure>
    <time_frame>Baseline</time_frame>
    <description>(Albumin, weight, BMI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nutritionnal status</measure>
    <time_frame>at day 5</time_frame>
    <description>(Albumin, weight, BMI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nutritionnal status</measure>
    <time_frame>7 days after the end of parenteral nutrition</time_frame>
    <description>(Albumin, weight, BMI)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Dietary and Nutritional Therapies</condition>
  <arm_group>
    <arm_group_label>Médialipides</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>parenteral nutrition by Médialipides (dosage form depending child's weight as recommended by the SPC)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SmofLIPID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>parenteral nutrition by Smoflipid (dosage form depending child's weight as recommended by the SPC)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Smoflipid</intervention_name>
    <arm_group_label>SmofLIPID</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Médialipides</intervention_name>
    <arm_group_label>Médialipides</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  0-18 years

          -  Solid Tumors

          -  hematological malignancies

          -  Requiring parenteral nutrition during at least 5 days

          -  With a central catheter

          -  With a normal hepatic function test

        Exclusion Criteria:

          -  Liver function tests disrupted

          -  Patient with a tumor or liver metastases

          -  Patient with against-indication to the use of lipid
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Marilyne POIREE, MD</last_name>
    <email>poiree.m@chu-nice.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Cassandre LANDES</last_name>
    <email>landes.c@chu-nice.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hôpital de l'Archet - CHU de Nice</name>
      <address>
        <city>Nice</city>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marilyne POIREE, MD</last_name>
      <email>poiree.m@chu-nice.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <lastchanged_date>August 31, 2015</lastchanged_date>
  <firstreceived_date>August 11, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Parenteral Nutrition</keyword>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
